On March 20, 2019, the Board of Directors of Ocular Therapeutix, Inc. following the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the size of the Board from eight to nine directors and elected Leslie J. Williams as a member of the Board to fill the newly created directorship. The election was effective as of March 20, 2019. Ms. Williams was designated as a Class II member of the Board to serve until the 2019 annual meeting of the stockholders of the Company and thereafter until her successor has been duly elected and qualified, or until her earlier death, resignation or removal. Ms. Williams is the founder of ImmusanT, Inc., a biotechnology company, and has served as a member of its board of directors and as its President and Chief Executive Officer since its inception in December 2010. She served as the President and Chief Executive Officer and as a member of the board of directors of Ventaira Pharmaceuticals, Inc., a specialty pharmaceutical company, from 2004 until 2008.